SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
BOSTON, March 07, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), an orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a conference call and live audio webcast on Tuesday, March 14, 2017, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2016, and provide a business update.
To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13654743. The live audio webcast will be accessible from the Investors page of Albireo’s website, ir.albireopharma.com.
To ensure a timely connection to the call or webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.
About Albireo
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson 6 Degrees 980-938-0260 [email protected]
